NAD+

Nicotinamide Adenine Dinucleotide

Evidence & Status

  • Preliminary / Experimental
  • Preliminary

At a Glance

Oxidized NAD+ studied mainly through direct IV disposition and short-term tolerability research. Direct human evidence exists, but therapeutic effectiveness and wellness or longevity benefits remain limited and uncertain.

Plain English

NAD+ is a molecule used throughout cells in energy and redox chemistry. Researchers are studying what happens when NAD+ itself is given by IV infusion, which is different from taking precursors such as NR or NMN. Early human studies describe disposition and short-term tolerability, not proven anti-aging, cognitive, energy, or disease benefits.

Overview

NAD+ is oxidized nicotinamide adenine dinucleotide, a cellular coenzyme involved in redox reactions and metabolism. This record concerns direct NAD+ administration research, especially IV infusion. NAD+ is not interchangeable with NADH, NR, NMN, niacin, nicotinamide, or the broader category of NAD boosters; evidence from precursors is not direct NAD+ administration evidence.

Research Summary

Direct human NAD+ administration evidence is limited to early research. A six-hour IV infusion pilot examined changes in the human plasma and urine NAD+ metabolome, supporting disposition and metabolite observations rather than longevity, cognitive, energy, or disease efficacy. A separate retrospective real-world pilot compared IV NAD+ and NR for short-term tolerability; its symptoms and findings are study-specific and are not randomized efficacy evidence. Broad wellness, anti-aging, longevity, and metabolic-optimization claims remain inadequately established.

Research Areas

  • NAD+ metabolism
  • Mitochondrial biology
  • DNA repair
  • Sirtuin biology
  • Direct IV NAD+ disposition
  • Human tolerability research

Safety & Risks

Serious Risks

  • Long-term safety of direct IV NAD+ administration is not established.
  • IV administration carries procedure-related risks and should not be treated as a wellness protocol.
  • The retrospective IV NAD+ tolerability pilot provides short-term, study-specific evidence rather than randomized efficacy evidence.

Reported Side Effects

  • Symptoms reported in specific direct IV NAD+ studies are study-specific and do not establish a general safety profile.
  • Nausea or transient fatigue may occur in reported infusion research contexts.
United States
No approved therapeutic NAD+ product or indication is established by the sources represented in this record.
United Kingdom
No approved therapeutic NAD+ product or indication is established by the sources represented in this record.
Australia
No approved therapeutic NAD+ product or indication is established by the sources represented in this record.
Canada
No approved therapeutic NAD+ product or indication is established by the sources represented in this record.

Citations & Sources